Loading stock data…
RGNT
$2.87-0.04 (-1.37%)
Market ClosedLast close May 1
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.87
Potential Upside
5%
Whystock Fair Value$3.01
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$10.00+248.4%
Range$10.00 – $10.00
Fundamentals
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen fo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$15.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-287.69%
Volume
Today's trading volume
5,095
Recent News
Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch
Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) is one of the best up and coming penny stocks to buy. On February 4, Regentis Biomaterials appointed Ori Gon as Chief Financial Officer and Chief Business Officer to lead the company’s financial strategy and commercial development. Gon joined the regenerative medicine firm as its lead product, GelrinC, nears commercial launch […]
Sector Update: Health Care Stocks Slide Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index and the Health
Sector Update: Health Care Stocks Softer in Afternoon Trading
Health care stocks declined Thursday afternoon with the NYSE Health Care Index dropping 0.5% and the